FDA Approves GSK's Hibsago for Chronic Hepatitis B Treatment

The U.S. Food and Drug Administration has approved GSK's Hibsago (bepirovirsen) for treating chronic hepatitis B virus (HBV) in certain adult patients. This first-in-class antisense oligonucleotide received priority review and Breakthrough Therapy Designation. The approval marks a significant medical advancement, offering a potential for functional cure rates previously unprecedented with existing standard treatments for this chronic infection.